2-(1,3-benzothiazol-2-ylmethylthio)-1-butyl-5-benzimidazolesulfonamide

2-(1,3-Benzothiazol-2-ylmethylthio)-1-butyl-5-benzimidazolesulfonamide, also known as **BMS-345541**, is a potent and selective **inhibitor of the enzyme protein kinase B (PKB)**, more commonly known as **Akt**.

**Akt** is a serine/threonine-specific protein kinase that plays a critical role in a variety of cellular processes, including cell survival, growth, and proliferation. It is frequently **overactive in cancer cells**, promoting their survival and growth.

**BMS-345541** inhibits Akt by binding to its active site, preventing it from phosphorylating its target proteins and thus blocking its downstream signaling pathways. This makes BMS-345541 a promising candidate for the **treatment of various cancers**, including **breast cancer, leukemia, and prostate cancer**.

**Why is it important for research?**

* **Novel Cancer Therapy:** BMS-345541 represents a novel approach to cancer therapy by targeting Akt, a key enzyme involved in cancer cell survival and growth.
* **Understanding Akt's Role:** The development of potent and selective inhibitors like BMS-345541 has helped researchers better understand Akt's role in various cellular processes and its significance in cancer development.
* **Drug Development:** BMS-345541 has been extensively studied in preclinical and clinical trials, providing valuable data for the development of new Akt inhibitors with improved efficacy and safety profiles.
* **Potential for Other Applications:** Akt is involved in various other biological processes beyond cancer, including inflammation and metabolic disorders. BMS-345541 and similar inhibitors could have therapeutic potential in these areas as well.

However, it's important to note that BMS-345541 is still under development and is not currently approved for any therapeutic use. More research is needed to assess its long-term safety and efficacy in humans.